The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable ...
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead ...
Traumatic brain injury is a leading cause of death and disability Currently, there is no treatment to prevent the long-term effects of traumatic brain injury Findings could translate into treating ...
The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback